Atrial fibrillation. Current recommendations for diagnosis and treatment

被引:1
作者
Kirchhof, P. [1 ,2 ,3 ,4 ]
机构
[1] Univ Birmingham, Inst Biomed Res, Ctr Cardiovasc Sci, Birmingham B15 2TT, W Midlands, England
[2] SWBH NHS Trust, Birmingham B15 2TT, W Midlands, England
[3] Univ Klinikum Munster, Munster, Germany
[4] Kompetenznetz Vorhofflimmern, Munster, Germany
来源
INTERNIST | 2013年 / 54卷 / 05期
关键词
Atrial fibrillation; Hemorrhage; Stroke; Catheter ablation; Cardioversion; Antiarrhythmic drugs; EXTERNAL CARDIOVERSION; FOLLOW-UP; AMIODARONE; MECHANISMS; MANAGEMENT; WARFARIN; TRIAL; TERM;
D O I
10.1007/s00108-013-3271-2
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Atrial fibrillation (AF) is by far the most common arrhythmia. It occurs more often with increasing age. Patients with AF almost always require oral anticoagulants and a rate-control treatment. In addition, other cardiovascular diseases must also be carefully treated in order to reduce the risks of cardiovascular complications from AF. Most patients profit from rate-control treatment with drugs that slow the conduction of the electrical impulse through the AV node. The aim is a resting heart rate of 100-110/min. If patients suffer from AF whilst on optimal rate control therapy, rhythm-control treatment with antiarrhythmic drugs, cardioversion or catheter ablation is indicated. The choice of the rhythm-control therapy should be made based on safety considerations. Whether achieving sinus rhythm beyond improvement of symptoms improves the prognosis of AF is tested in ongoing trials.
引用
收藏
页码:583 / 593
页数:11
相关论文
共 50 条
  • [21] Cardiac pacing for the prevention of atrial fibrillation.: A current review
    Yang, A
    Bitzen, A
    Schwab, JO
    Schrickel, J
    Lüderitz, B
    Lewalter, T
    HERZ, 2005, 30 (08) : 733 - 742
  • [22] Cardioversion in atrial fibrillation. Focus on recent-onset atrial fibrillation
    Tampieri, Andrea
    Rusconi, Anna Maria
    Lenzi, Tiziano
    INTERNAL AND EMERGENCY MEDICINE, 2012, 7 : S241 - S250
  • [23] Current Recommendations on Atrial Fibrillation: A Comparison of the Recent European and Canadian Guidelines
    Okutucu, Sercan
    Gorenek, Bulent
    CARDIOLOGY, 2022, 147 (01) : 81 - 89
  • [24] Treatment of atrial fibrillation
    Kirchhof, P.
    Breithardt, G.
    INTERNIST, 2007, 48 (08): : 819 - 829
  • [25] Rate and rhythm control in atrial fibrillation. Pharmacological approaches
    Weipert, K. F.
    Erkapic, D.
    Schmitt, J.
    HERZ, 2015, 40 (01) : 16 - 24
  • [26] Pharmacological Cardioversion With Antazoline in Atrial Fibrillation.
    Wybraniec, Maciej T.
    Wrobel, Wojciech
    Wilkosz, Katarzyna
    Wrona, Karolina
    Bula, Karolina
    Wojakowski, Wojciech
    Gasior, Zbigniew
    Mizia-Stec, Katarzyna
    CIRCULATION, 2018, 138
  • [27] Cardioversion in atrial fibrillation. Focus on recent-onset atrial fibrillation
    Andrea Tampieri
    Anna Maria Rusconi
    Tiziano Lenzi
    Internal and Emergency Medicine, 2012, 7 : 241 - 250
  • [28] Stroke prophylaxis in atrial fibrillation. When, how and for whom?
    Maurer, T.
    Sohns, C.
    HERZ, 2017, 42 (04) : 373 - 379
  • [29] Stroke Prevention in Atrial Fibrillation: Current Strategies and Recommendations
    Naccarelli, Gerald V.
    Caputo, Gregory
    Abendroth, Thomas
    Faber, Samuel
    Sendra-Ferrer, Mauricio
    Wolbrette, Deborah
    Samii, Soraya
    Hussain, Sarah
    Gonzalez, Mario
    CARDIOVASCULAR INNOVATIONS AND APPLICATIONS, 2016, 1 (02) : 157 - 164
  • [30] Adherence to recommendations of the Therapeutic Positioning Report about treatment with oral anticoagulants in elderly patients with atrial fibrillation. The ESPARTA study
    Suarez Fernandez, Carmen
    Maria Mostaza, Jose
    Castilla Guerra, Luis
    Cantero Hinojosa, Jesus
    Maria Surinach, Josep
    Acosta de Bilbao, Fernando
    Jose Tamarit, Juan
    Diaz Diaz, Jose Luis
    Luis Hernandez, Jose
    Cazorla, Daniel
    Rafols, Carles
    MEDICINA CLINICA, 2018, 151 (01): : 8 - 15